Diagnosis, Staging and Treatment of Patients with Gestational Trophoblastic Disease

Objectives

The national clinical guideline provides an evidence-based framework for the diagnosis, staging, treatment, surveillance and end-of-life care of patients with gestational trophoblastic disease (GTD) in Ireland. It seeks to improve the quality, safety, consistency and cost-effectiveness of care, support prompt diagnosis and best available treatment, and improve survival, patient outcomes and quality of life while reducing avoidable morbidity and mortality.[1][2][3]

GTD includes premalignant and malignant disorders arising from gestational trophoblastic cells; its malignant conditions are collectively termed gestational trophoblastic neoplasia (GTN).[4]The guideline sits within the National Cancer Control Programme's wider remit to prevent and treat cancer and improve survival and quality of life through research- and surveillance-informed strategies.[1]

• Standardise diagnosis through histopathological assessment where available, ultrasound, serum human chorionic gonadotrophin (hCG) measurement, timely pathology reporting and early specialist referral where GTD is clinically, radiologically or biochemically suspected.[5][6][7]
• Centralise management and hCG surveillance through a maximum of two specialist centres and a National GTD Registry, Monitoring and Advisory Centre covering all GTD cases.[6][8]
• Guide staging and treatment using International Federation of Gynecology and Obstetrics staging and modified World Health Organization prognostic scoring, distinguishing low-risk from high-risk GTN and directing chemotherapy accordingly.[9][10]
• Provide single-agent methotrexate, with or without folinic acid, or actinomycin-D for low-risk GTN, and multi-agent EMA/CO, comprising etoposide, methotrexate, actinomycin-D, cyclophosphamide and vincristine, for high-risk disease.[11][12]
• Maintain remission through consolidation chemotherapy after hCG normalisation, escalate treatment for resistance or relapse, and individualise treatment for rare or ultra-high-risk metastatic presentations.[13][14][15]
• Preserve reproductive health where possible, including early ultrasound in subsequent pregnancies to confirm a normal intrauterine pregnancy and exclude recurrent molar pregnancy.[16][17]

Implementation

Delivery relies on multidisciplinary clinical teams, specialist gynaecological and medical oncology expertise, nationally coordinated hCG monitoring, and accountable hospital leadership.[2][3][18]The National Cancer Control Programme, within the Health Service Executive, developed and funds the guideline, while the National Clinical Effectiveness Committee provides national leadership, quality assurance and alignment with implementation mechanisms.[1][19]

Recommendations were developed through Evidence-Based Practice, combining research evidence, clinical expertise, Irish applicability, patient benefits and harms, health-system effects and resource implications.[19][20]Clinical questions were formulated using the Population, Intervention, Comparator, Outcome and, where relevant, Time framework; international guidelines and primary literature were systematically searched, critically appraised and graded.[19][21][22]

• Engage a multidisciplinary Guideline Development Group comprising relevant clinical specialists, pharmacists, nursing, librarians, research staff, a health economist, a statistician and methodological personnel, alongside stakeholder and international expert review.[23][20]
• Involve patient advocacy groups in national stakeholder review and in the development of patient information, while requiring submitted feedback to be evidence-supported and accompanied by conflict-of-interest declarations.[24][20]
• Apply the COM-B behaviour-change model, addressing capability, opportunity and motivation through education, training, enablement, persuasion, incentivisation, modelling, restrictions and environmental restructuring.[25][7]
• Identify implementation barriers and facilitators during recommendation meetings, record them in considered judgement forms, and support delivery through clinical protocols, tools and procedures.[7][18]
• Disseminate the guideline through professional networks and the websites of the National Cancer Control Programme and National Clinical Effectiveness Committee.[18][26]
• Assign corporate responsibility to each hospital's Chief Executive Officer, General Manager and Clinical Director, while requiring multidisciplinary team members to implement recommendations within their professional discipline and competence.[18][5]

The proposed national registry and advisory centre is the principal operational mechanism for centralised surveillance. It is located at Cork University Maternity Hospital and includes a Clinical Director, two Clinical Nurse Specialists each employed at 0.5 whole-time equivalent, and one whole-time equivalent secretarial post.[27]The referring consultant retains overall responsibility, while the centre provides central hCG recording, reminders, clinical review, advice and multidisciplinary discussion.[27]

• Register patients with complete or partial hydatidiform mole, relevant twin pregnancies and limited molar change requiring follow-up, subject to consent.[27]
• Undertake hCG assays weekly until normalisation and then at four-week intervals until follow-up is complete, with daily case review and national multidisciplinary team teleconferences every two weeks.[27]
• Notify treating clinicians when hCG monitoring indicates that further intervention is required and discuss complicated cases with the registry clinical lead.[8]
• Prioritise preliminary pathology reports for suspected molar pregnancy, ideally making them available within 14 days.[6][28]
• Provide initial low-risk chemotherapy courses as an inpatient in centres with medical oncology, gynaecological and interventional radiology services, then deliver uncomplicated subsequent courses through medical oncology day wards.[29]
• Seek international expert input for relapsed high-risk disease and rare hepatic, cerebral or synchronous metastatic presentations.[30][31]

Implementation is incorporated into the Health Service Executive and National Cancer Control Programme service-planning process, with annual GTD priorities and additional resources for recommendations requiring service change sought through that process.[18][26]Establishing the registry and advisory centre is estimated at approximately 107,000 euro, with ongoing maintenance estimated at approximately 134,000 euro annually.[28]

Governance includes quarterly performance-monitoring and service-planning meetings between the Cancer Network Manager and cancer-centre leadership, nomination of a gynaecological oncology lead clinician in each cancer centre, clinical audit of implementation and patient outcomes, and annual reporting against key performance indicators set by the clinical governance group under the National Cancer Control Programme.[24][18][27]The guideline is subject to periodic literature surveillance and consideration for review after three years, with updates submitted to the National Clinical Effectiveness Committee for approval.[18]

Monitoring & Evaluation

Monitoring and accountability combine clinical surveillance, registry-based audit, guideline implementation review and evidence-quality assurance. Human chorionic gonadotrophin (hCG) monitoring is the principal clinical indicator for diagnosis, treatment response, remission and follow-up, while the proposed National Gestational Trophoblastic Disease Registry, Monitoring and Advisory Centre supports centralised case recording, review and outcome monitoring.[8][32][27]

• Monitor hCG weekly after complete or partial hydatidiform mole until normalisation, then continue follow-up according to mole type and timing of normalisation.[8][16]
• Measure hCG twice weekly during low-risk treatment and fortnightly after remission until one year of normal results is documented.[13][29][33]
• Use rising hCG in two successive weekly measurements, plateauing hCG across three weekly measurements, and treatment toxicity as criteria for reviewing or changing first-line treatment.[14][33]
• Use FIGO anatomical staging and the modified World Health Organization prognostic score to classify risk, guide chemotherapy and enable comparison of outcomes between treatment centres.[9][34]
• Maintain a centralised registry and hCG surveillance system to record cases, audit referrals, identify patients needing intervention and monitor disease resolution and treatment outcomes.[8][32][27]
• Report annually against key performance indicators determined by the clinical governance group under the auspices of the National Cancer Control Programme.[27]
• Audit implementation and patient outcomes against the guideline audit criteria to assess effects on patient care.[18]
• Review the guideline through periodic literature surveillance, consider formal review after three years, and submit interim or revised updates for National Clinical Effectiveness Committee approval.[18]
• Maintain records of stakeholder and international expert submissions, amendments and related decisions during guideline development and review.[20][18][25]
• Monitor implementation and service planning through quarterly meetings between the Cancer Network Manager and each cancer centre’s chief executive officer or general manager.[24]

National Clinical Guidelines are intended to be supported by clinical audit, and the National Clinical Effectiveness Committee has responsibility for quality assurance, clinical-audit processes and periodic reporting on guideline implementation, impact and audit performance.[1]The National Cancer Control Programme also uses research and surveillance to inform cancer-control strategies.[1]

Evidence assurance includes appraisal of guidelines and primary studies, consideration of validity, significance, applicability, benefits, harms, health-system impact and resource implications, and grading of recommendations according to evidence strength and directness.[19][20]Literature-search records, retraction alerts and final checks that cited evidence has not been withdrawn are also required.[35]

The source does not provide the detailed registry dataset, full audit criteria, key-performance-indicator definitions, reporting template or independent post-implementation evaluation results.[27][7][36]Hospital In-Patient Enquiry data provide useful epidemiological information, but their interpretation is limited by incomplete reporting, inconsistent definitions, lack of a unique patient identifier and possible double counting across hospitals.[37]

Costing & Financing

The guideline recognises cost-effectiveness, health-system impact and resource implications as relevant to clinical decision-making.[1][20]Many recommendations are expected to be cost neutral because they reflect existing standard practice, while additional resources required for changes should be pursued through the Health Service Executive service-planning process.[18]

• Fund the guideline development process through the National Cancer Control Programme while maintaining independence of guideline content and recommendations from the funder and other interests.[19]
• Resource the National Gestational Trophoblastic Disease Registry, Monitoring and Advisory Centre with a Clinical Director, two 0.5 whole-time-equivalent Clinical Nurse Specialist posts and one whole-time-equivalent secretarial post.[27]
• Provide staffing, office and information-technology capacity for the registry and centre, alongside training and access to imaging and radiology services.[36]
• Estimate registry establishment at approximately 107,000 euros and ongoing maintenance at approximately 134,000 euros annually.[28]
• Absorb additional imaging for approximately 25 to 30 women annually within existing budgets as an opportunity cost, without additional equipment or staff.[28]
• Recognise that expedited pathology reporting is not expected to have a substantial resource impact, although it may increase pressure on already overstretched hospitals.[28]

The economic review found limited evidence on cost-effective gestational trophoblastic disease management and health-service resource effects.[38]From a payer perspective, eight-day methotrexate with folinic acid was the least expensive of three first-line low-risk gestational trophoblastic neoplasia strategies, whereas weekly methotrexate was the most expensive.[38]The converted euro estimates use purchasing-power-parity adjustments for exchange rates, purchasing power and health inflation, but are indicative only because international cost data may not transfer directly to Ireland.[39]

A United Kingdom service model was considered broadly relevant because of similarities in epidemiology, patient characteristics and treatment pathways, although setting and cost-data differences limit transferability.[38]National or regional publicly funded specialist services were identified as a potentially generalisable model for optimising low-risk care.[38]

No overall Irish implementation budget, financing allocation, funding gap, quantified resource-mobilisation plan or complete economic model is specified.[38][28]